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Abstract
Molecular interrogation of a biological sample through DNA sequencing, RNA and microRNA profiling, proteomics and other
assays, has the potential to provide a systems level approach to predicting treatment response and disease progression,
The authors are researchers in bioinformatics, biostatistics and systems biology, spanning a wide range of geographic locations and topical areas. All are
actively engaged in analysis and methods development for multi-assay omics experiments.
Lavanya Kannan is a researcher at the City University of New York School of Public Health at Hunter College, and is involved in methods of integrating
and visualizing genomic data in Bioconductor. Her interests include network biology, phylogenetics and data integration.
Marcel Ramos is a research associate at the City University of New York School of Public Health at Hunter College. He is working on tools for obtaining The
Cancer Genome Atlas data as ready-to-use data sets.
Angela Re holds a postdoctoral fellowship at the Centre for Integrative Biology at the University of Trento. She is interested in the analysis of genomics data to
study post-transcriptional regulatory mechanisms, their inclusion in regulatory pathways along with their potential relevance in cancer prognosis.
Nehme El-Hachem is doing a PhD in biomedical sciences at the Universite´ de Montre´al under the supervision of Dr Haibe-Kains. His main research inter-
ests include pharmacogenomics, toxicogenomics, drug repositioning in cancer as well as personalized medicine and disease management.
Zhaleh Safikhani is a postdoctoral research fellow at Princess Margaret Cancer Centre, Canada. She is currently investigating the association between
tumor-specific transcripts and drug sensitivity.
Deena M.A. Gendoo is a postdoctoral research fellow at the Princess Margaret Cancer Centre, Canada. Her research focuses on translational bioinformatics
in multiple cancer types, as well as pharmacogenomics and drug repurposing for personalized medicine.
Sean Davis is a pediatric oncologist at the National Cancer Institute of the National Institutes of Health who works broadly in the areas of genomics and
bioinformatics of high-throughput data. He has a strong interest in developing software and tools for interpreting genomic data and leveraging public
data for discovery.
David Gomez-Cabrero is an assistant professor in the Unit of Computational Medicine at Karolinska Institutet in Sweden, with a background in statistics
and mathematics. His research interests are in transcriptomics and methylation analysis, and particularly integration of multi-omics data sets.
Robert Castelo is an associate professor of Bioinformatics and Biostatistics at the Universitat Pompeu Fabra in Barcelona, Spain. His research interests lie
at the intersection of statistics, machine learning, genetics and genomics.
Kasper D. Hansen is an assistant professor in Biostatistics at Johns Hopkins University. He works on statistical approaches to analyze high-throughput
biological data and is a longtime contributor to the Bioconductor project.
Vince Carey is an associate professor of Medicine (Biostatistics) at Harvard Medical School and has been a core developer of Bioconductor since its
inception.
Martin Morgan is an associate professor in Biostatistics and Bioinformatics at Roswell Park Cancer Institute, and current leader of the Bioconductor project
for the analysis and comprehension of high-throughput genomic data.
Aedı´n C. Culhane is a research scientist at the Dana-Farber Cancer Institute, Boston. Her research includes analysis of high-throughput data arising from gen-
omic, transcriptomic and proteomic studies of cancer, with a particular focus on meta analysis and integration of data from multiple studies.
Benjamin Haibe-Kains is principal investigator at thePrincess Margaret Cancer Centre. His research focuses on the integration of high-throughput data
from various sources to improve biomarker discovery, especially in cancer.
Levi Waldron is an assistant professor of biostatistics at the City University of New York School of Public Health at Hunter College, with research interests
in integrative genomic data analysis of cancer.
Submitted: 12 May 2015; Received (in revised form): 29 July 2015
VC The Author 2015. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
603
Briefings in Bioinformatics, 17(4), 2016, 603–615
doi: 10.1093/bib/bbv080
Advance Access Publication Date: 12 October 2015
Paper
and to developing precision therapies. Large publicly funded projects have generated extensive and freely available multi-
assay data resources; however, bioinformatic and statistical methods for the analysis of such experiments are still nascent.
We review multi-assay genomic data resources in the areas of clinical oncology, pharmacogenomics and other perturbation
experiments, population genomics and regulatory genomics and other areas, and tools for data acquisition. Finally, we review
bioinformatic tools that are explicitly geared toward integrative genomic data visualization and analysis. This review provides
starting points for accessing publicly available data and tools to support development of needed integrative methods.
Key words: multiple assays (multi-assays); public data; bioconductor; integrative genomics; cancer; pharmacogenomics;
omics
Introduction
The falling cost of genomic assays has enabled more
comprehensive molecular profiling, also referred to as ‘omics’,
of biological specimens for developing systems approaches to
molecular biology, studying disease etiology and improving
treatment outcomes [1]. The growth of ‘multi-assay’ genomic
experiments is led by major public projects such as The Cancer
Genome Atlas (TCGA) and the International Cancer Genome
Consortium (ICGC) [2], but smaller-scale projects are increas-
ingly being undertaken by individual laboratories and deposited
in public databases such as the National Center for
Biotechnology Information (NCBI) Gene Expression Omnibus
(GEO) [3] and European Bioinformatics Institute (EBI)
ArrayExpress [4] databases. We define ‘integrative’ analysis in
this context as analysis that spans multiple molecular data
types, including, for example, somatic mutations, copy number,
DNA methylation, messenger RNA (mRNA) expression and
protein abundance. It can include other data types such as
metabolite abundance and microbiome profiling, as well as
metadata such as clinical outcome and tumor pathology in can-
cer studies. Even though generation of multi-assay molecular
data sets has become common, integrative data analysis
remains a significant challenge and has been limited primarily
to those laboratories with substantial bioinformatic expertise
(e.g. [5–7]).
The objective of this article is to accelerate the development
of bioinformatic and statistical methodology that facilitate the
integrative analysis of multi-assay genomics experiments. We
do this by reviewing appropriate data from various fields that
are in the public domain and that can be used for the develop-
ment of new analytical approaches. Sources of these data in-
clude large consortial projects in clinical oncology,
pharmacogenomics and other cell line perturbation experi-
ments, population genomics and regulatory genomics. We re-
view additional data available from smaller experiments
performed by individual laboratories that have deposited data
in public databases. We also review tools that simplify acquisi-
tion of these data, primarily for TCGA and for GEO. Finally, we
conclude by summarizing the current state of tools for integra-
tive genomic data analysis and discussing the gaps left by these
tools.
Clinical oncology
Major data-generating projects provide numerous genomic
assays mostly from resected primary tumors, along with clinical
and histopathological data. They represent the most compre-
hensive collections of multi-assay genomic data sets currently
available, and important test cases for related methodological
development.
The Cancer Genome Atlas
Under the umbrella organization of the National Institutes of
Health (NIH), the TCGA project is a joint collaboration between
the National Cancer Institute (NCI) and the National Human
Genome Research Institute (NHGRI) aimed at understanding the
molecular basis of cancer. It is the largest available resource for
multi-assay cancer genomics data, and aims to profile over
11 000 patients representing 36 cancer types, using up to 15
genomic assays per tumor, in combination with clinical and
pathological annotations. The TCGA PanCanAtlas project has
described integrative analysis across 12 tumor types (http://
www.nature.com/tcga/). Most cancer types are still in progress;
a snapshot at the time of writing of the number of data types
currently available per cancer type is provided in Figure 1.
Numerous tools, summarized in Table 1, have been developed
to simplify the daunting process of data acquisition from this
project.
International Cancer Genome Consortium
The ICGC currently coordinates 55 research projects, which col-
lectively aim at obtaining a complete catalog of alterations that
characterize the genome, transcriptome and epigenome in 50
forms of tumor that mainly contribute to the burden of disease
in people throughout the world. The ICGC data portal (https://
dcc.icgc.org/) provides tools for visualizing, querying and down-
loading the data released quarterly by the consortium’s member
projects. It also provides basic analysis.
Molecular Taxonomy of Breast Cancer International
Consortium
The Molecular Taxonomy of Breast Cancer International
Consortium (METABRIC) data set (http://molonc.bccrc.ca/apari-
cio-lab/research/metabric/) contains clinical traits, expression,
copy number variation profiles and single nucleotide poly-
morphism (SNP) genotypes derived from breast tumors
collected from participants of the METABRIC trial [18].
Pharmacogenomics and other perturbation experiments
Cancer cell lines are widely used as preclinical models to gain
mechanistic and therapeutic insight. Common approaches
include pharmacogenomics, and application of genetic perturb-
ation reagents (such as shRNAs or cas9/sgRNAs) to silence or
knock-out individual genes and identify those genes that affect
cell survival. This section describes large-scale molecular and
pharmacological characterization of human cancer cell lines for
which multi-assay data are publicly available. Substantial
overlap exists in both the cell lines and compounds used by
these studies, offering still unrealized potential for large-scale
604 | Kannan et al.
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Figure 1. Data and cancer types provided by TCGA. The top barplot shows the number of data types available for each of the 36 cancer types (key provided as
Supplementary Table S1) as of January 2015. Cancer types with fewer data types are still in the process of data collection. The lower barplot shows the number of can-
cer types for which each data type is available (key provided as Supplementary Table S2).
Table 1. TCGA data acquisition tools
Name and citation Description Download
type
Data
analysis
integration
Data level Software implementation
RTCGAToolbox [8] R package for downloading
preprocessed data
Bulk High 3–4 ’RTCGAToolbox’ - Bioconductor
Package
firehose_get [9] Unix command line tool Bulk Low 1–4 Command line, wget
Linked TCGA [10]
5 star-linked open data
via SPARQL endpoints
Bulk Low 3 Resource Description
Framework (RDF) and
SPARQL query endpoints
MSKCC cBioPortal
[11, 12]
R package and Web inter-
face to the MSKCC Cancer
Genomics Data Server
Limited High 3–4 ’cgdsr’—R Package
UCSC Cancer
Genomics Hub [13]
Restricted access tool to
raw data files
Bulk Low 1 GeneTorrent client
(gtdownload)
TCGA Assembler [14] R script files for download-
ing preprocessed data
Bulk Medium 1, 3 Collection of R scripts
Synapse client [15] Download within R using
Synapse syntax (creden-
tials required)
Limited Medium 1–4 ’synapseClient’—R Package
TCGA Data Portal
[16]
Bulk, table and HTTP-link-
based repository
Variable Low 1–4 Web site and Web client
TCIA Imaging
Archive [17]
Repository for medical
images of cancer in
DICOM format
Bulk – 1 Web site download
’Data levels’ are defined by TCGA, varying from 1 (raw data) to 4 (data analysis resulting from multiple samples, such as regions of common copy number variation).
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integration (Figure 2). Table 2 summarizes these pharmacoge-
nomic and perturbation cell line data sets.
The NCI-60 cell line panel
The NCI-60 panel of 59 human tumor cell lines are perhaps
some of the most extensively characterized cell lines [19]. Data
sets from these cell lines include protein levels, RNA measure-
ments, mutation status, and enzyme activity levels. The
molecular and pharmacological data are publicly available on
the CellMiner (http://discover.nci.nih.gov/cellminer/) [20] and
DTP (http://dtp.cancer.gov/mtargets/mt_index.html) Web sites,
respectively. Published studies reported results from integrative
analysis of DNA copy number with gene expression levels, and
drug sensitivities have been performed [21, 22]. Limited integra-
tive analysis tools are available through CellMiner, for users
who wish to investigate the molecular basis of drug response in
the NCI-60 cell line panel. The NCI-60 proteomic data can be
downloaded from http://wzw.tum.de/proteomics/NCI60/as well
as from https://www.proteomicsdb.org.
Numerous projects provide additional pharmacological and
perturbation experimental results on the NCI-60 cell lines.
Notably, the In Vitro Cell Line Screening Project screens up to
3000 compounds per year for potential anticancer activity on
these cell lines. However, this and other experiments using the
NCI-60 cell lines are not accessible through CellMiner and
require additional curation and processing to enable integrative
analysis with the base genomic characterizations. Lack of
standardization in cell line and drug names is a challenge that
can require careful inspection to resolve [23].
The Cancer Cell Line Encyclopedia
The Cancer Cell Line Encyclopedia (CCLE) data set is a compil-
ation of gene expression, copy number and DNA sequencing
data from 947 human cancer cell lines. It also comprises the
pharmacological profiles for 24 anticancer drugs across 504 of
the cell lines (http://www.broadinstitute.org/ccle). Barretina and
colleagues demonstrate multi-assay analysis of these samples
in identifying genetic, cell-of-origin and gene-expression-based
predictors of drug sensitivity using these two data sets [24]. This
data set provides a platform to integrate different assays that
link pharmacologic vulnerabilities to molecular patterns and to
develop new companion tests for targeted chemotherapies [25].
The metadata of pharmacologic profiling and expression micro-
array describe the inconsistency in names that are used for the
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Figure 2. Overlap across publicly available pharmacogenomic data sets. (A) Cell lines that have been molecularly and/or pharmacologically profiled in each study. (B)
Drug compounds screened in each study. The substantial overlap across large pharmacogenomic studies using different molecular and pharmacological profiling
assays enables integrative analysis to define more robust biomarkers of drug response.
Table 2. Multi-assay pharmacogenomic and perturbation cell line data sets
Program
name
Number of
unique
cell lines
Number
of unique
tissues of
origin
Assay Number of
drugs tested
FDA-approved
drugs
CMAP 5 4 GE array 1,309 576
L1000 77 15 GE array 20,431 851
NCI60 60 9 GE array, SNP array, RPPI 49,938 201
CGP 727 32 GE array, WXS; SNP array 140 29
CCLE 1036 24 GE array and RNA-seq, WXS/WGS; SNP
array
24 8
CTRP 242 17 See CCLE 354 36
CTD2 243 20 DNA-seq, GE array, RPPA, perturbation-
based screens, Comparative Genomic
Hybridizations
355 35
GDSC 714 14 GE array, genetic mutations 142
Achilles 216 GE array, genetic mutations, phenotypic
information
54,020
LINCS 356 RNAseq, Proteomics 5,943
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cell lines, which may be overcome by writing curation scripts to
map cell line names. However, the data set license restricts
redistribution of curated versions that would be more readily
integrated with other pharmacogenomic data resources.
Genomics of Drug Sensitivity in Cancer
Genomics of Drug Sensitivity in Cancer (GDSC) is a dedicated
academic research program of the Cancer Genome Project (CGP)
to study the therapeutic targets for cancer (http://www.cancer
rxgene.org/). The GDSC database (http://www.cancerrxgene.org/
) is a public resource containing data from about 75 000 experi-
ments on 142 anticancer drugs across almost 714 cell lines.
The compounds studied include cytotoxic chemotherapeutics
as well as targeted therapeutics from commercial sources,
academic collaborations and from the biotech and pharmaceut-
ical industries. Similar to CCLE, the large collection of cell lines
helps to capture genomic heterogeneity underlying human
cancer. Drug sensitivity patterns of the cell lines can be
correlated with expression data to identify genetic features that
are predictive of sensitivity, to identify mutated cancer genes
associated with cellular response to available cancer drugs [26].
The Cancer Therapeutics Response Portal
Cancer Therapeutics Response Portal (CTRP) provides open
access to quantitative sensitivity measurements to a 354-mem-
ber ‘Informer Set’ of small-molecule probes and drugs, for 242
genetically characterized cancer cell lines. Although CTRP does
not provide molecular profiles data, it contains selected cell
lines that have been molecularly characterized within CCLE,
making it possible to develop new biomarkers of drug response
[27]. Although the current implementation of the portal only
allows investigation of main features of their panel of cell lines,
small molecules and corresponding targets, future updates will
provide users with advanced clustering tools to investigate the
grouping of compounds based on their growth inhibitory effects
(Paul Clemons, ‘personal communication’).
Cancer Target Discovery And Development
Cancer Target Discovery And Development (CTD2) provides a
data portal (https://ctd2.nci.nih.gov/dataPortal/) to cell line
experiments produced by members of this research network
(including CTRP), each providing different types of data for par-
tially overlapping cancer cell lines. These data include DNA
sequencing, gene expression microarrays, comparative genomic
hybridization and reverse-phase protein lysate microarrays
(RPPA), as well as cytotoxicity screening and perturbation-based
screening (e.g. small interfering RNA library screening). Some
individual data sets provide multi-assay data [28], and
additional depth of integrative analysis of data from genomic
profiling and perturbation-based screenings could be gained by
combining complementary assays performed on the same cell
lines by different laboratories. However, the data formats (e.g.
soft,.txt and others) and cell line names (e.g. LN229 versus LN-
229) are not standardized, so additional curation is required to
integrate data sets originating from the different laboratories.
Genetic perturbations
Project Achilles
Project Achilles provides data sets to identify and catalog
genetic vulnerabilities across 216 genomically characterized
human cancer cell lines (http://www.broadinstitute.org/
achilles). The project uses 54 020 genome-wide genetic perturb-
ation reagents (shRNAs or cas9/sgRNAs) to silence or knock-out
around 11 000 individual genes and identify those genes that
affect cell proliferation and/or viability. When functional data
are integrated with information obtained by cancer genomes, it
is possible to reveal lineage-specific dependencies across a wide
range of cancers [29]. The project also provides relative
abundance assays for shRNA sequences, correlations of genetic
dependencies with cell proliferation and lineage-specific muta-
tions. Although not straightforward, network analysis is useful
for integrating these types of multiple assays that provide vari-
ous vulnerability measurements. Network analysis and other
methods [30–32] are useful in cataloging synthetic lethality, i.e.
finding minimal combinations of genes whose collective
inhibition is lethal. Such vulnerability studies provide targets
for therapy, and can be performed via integrating publicly
available data.
CCBR-OICR Lentiviral Technology Cancer
CCBR-OICR Lentiviral Technology (COLT)-Cancer [33] is a Web
interface for shRNA screens across multiple cancer cell lines
(http://dpsc.ccbr.utoronto.ca/cancer/). The database provides
shRNA dropout signature profiles, based on a lentiviral shRNA
screening library (78 432 shRNAs) targeting 16 000 genes in
over 70 cell lines from breast, pancreatic and ovarian cancer.
Both shRNA- and gene-activity rank profiles are computed
using a developed scoring method to assess their performance
in every experiment. Users can assess the activity performance
via gene-centric searches, as well as conduct ‘cross cell-line’
queries. Compared with the existing repositories of RNAi
screens for mammalian cell lines, which support the design of
RNAi screens and RNAi analysis of single systems, COLT-Cancer
facilitates comparison of essential genes across multiple cell
lines. Accordingly, this promises seamless integration of genetic
profile data with cancer genomic information, which serves to
aid in the identification and development of prognostics and
therapeutics for cancer.
Combination of drug and genetic perturbations
Library of Integrated Network-based Cellular Signals
The NIH Library of Integrated Network-based Cellular
Signatures (LINCS) project (http://www.lincsproject.org/) has
assembled 44 assays for approximately 5943 perturbagens
(perturbing agents) across 356 cell lines from six centers, to
catalog changes in gene expression and other cellular processes
that occur when cells are exposed to a variety of perturbing
agents. As part of LINCS, the Connectivity Map project investi-
gates effects of drug compounds on the transcriptional state of
cell lines [34, 35]. The most recent version of the Connectivity
Map is the L1000 data set, where expression of 1000 ‘landmark
genes’ [36] is measured for up to 77 cell lines, perturbed by
20 431 compounds. The remaining transcriptome is estimated
from a computational model based on thousands of gene
expression from the Gene Expression Omnibus. In addition to
small molecules and FDA-approved drugs, single gene knock-
down and overexpression are available for 5806 genetic perturb-
ations. The LINCS Canvas Browser [37] allows querying,
browsing and interrogating of LINCS data. The idea behind the
Connectivity Map and the LINCS project is to develop a tool to
accelerate the drug discovery process.
Population genomics
Population genomics examines the genomic variation within
and among populations. The most common tool used has been
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the SNP array, but current efforts include DNA sequencing, RNA
sequencing and other data types.
1000 Genomes Project
The 1000 Genomes Project aims to provide a comprehensive
resource for human genetic variants across the population.
Although deep sequencing (which requires 28 coverage) is still
expensive to recover the complete genotype of each sample, the
Project provides 4 coverage of the genomic regions, enough to
identify variants with frequencies as low as 1% in the popula-
tion. A validated haplomap (a catalog of genetic variants) of 38
million SNPs (98% of accessible SNPs) and 1.4 million short
insertions and deletions, among others using this low-coverage
whole genome and exome sequencing, have been reported by
the 1000 Genomes Project Consortium [38]. The project also
provides publicly available expression data (RNA sequencing
and expression arrays), which can be analyzed to determine
whether genetic variants are associated with changes in
expression.
dbSNP
NCBI’s dbSNP allows users to deposit short genetic variations
including SNPs in the Variant Call Format with an asserted
position of the variant, thereby providing accuracy in variant
mapping [37]. Data from the 1000 Genomes Project get submitted
to dbSNP, and longer structural variants get submitted to the
Database of Genomic Variants archive, which accounts for vari-
ations ranging from tens to millions of base pairs, including in-
sertions, deletions, inversions, translocations and locus copy
number changes. Although dbSNP contains a broad collection of
SNPs from multiple sources, additional curation and integration
of mRNA transcripts is required to perform functional analyses of
how the location of the variations affect phenotypic changes
such as metabolism and cell signaling. Because dbSNP was
developed to complement GenBank, it contains nucleotide
sequences from any organism. The human data in dbSNP
include submissions from the SNP Consortium, variations mined
from genome sequencing as part of the human genome project
and individual laboratory contributions of variations in specific
genes, mRNAs, Expressed Sequence Tags or genomic regions.
Exome sequencing projects
Whole-exome sequencing (WES) has been widely adopted, and
several initiatives have emerged to structure and gather the
large number of profiled samples. The most prominent ones are
the National Heart, Lung and Blood Institute Exome Sequencing
Project (http://evs.gs.washington.edu/EVS), which has WES data
for 6500 individuals diagnosed with heart, lung and blood
disorders, and the Exome Aggregation Consortium (http://exac.
broadinstitute.org), which has WES data for 60 706 unrelated
individuals sequenced as part of various disease-specific and
population genetic studies. These initiatives provide an unpre-
cedented depth to characterize rare variants located in exons.
British birth cohort study
The European Genome-phenome Archive (EGA) is the European
version of the service provided by dbSNP. The British birth
cohort study archive is set up to provide 10 TB of data from 1
million loci taken from 100 000 individuals from the Genomics
Englands’ Genome 10K project. In addition, the archive handles
both restricted patient data and freely available data after
phenotypic information of the individuals are removed. A
number of studies have been published since the initiation of
EGA, including genome-wide association study (GWAS) (http://
www.gwascentral.org/), cancer genomics (https://ocg.cancer.
gov/) and whole genome sequencing (http://www.illumina.com/
applications/sequencing/dna_sequencing/whole_genome_
sequencing.html), in addition to genotype and expression
analyses. These data have been used in key discoveries in com-
mon diseases, see for example [39–41].
Clinical covariates in consortial oncology projects
Omics data intended for the study of disease are far less useful
if not coupled with comprehensive clinical records. Yet,
standardizing and digitizing clinical data remains a challenge
that only in the recent years has started to be addressed [42].
Cancer consortium projects, such as TCGA or ICGC, can enforce
standards for the integration of clinical and molecular data pro-
duced within the consortium. However, even with such focused
efforts, it has been reported that much of the ICGC molecular
data lack key clinical information [43]. Storing molecular and
clinical data also requires maintaining patient’s anonymity and
matching patient’s consent to the use of their data. The NCBI
dbGaP database of genotypes and phenotypes [44] and EGA [45]
are two working instances of technological platforms meeting
those requirements.
Regulatory genomics
Encyclopedia of DNA Elements
The Encyclopedia of DNA Elements (ENCODE) Consortium is an
international collaboration of research groups funded by the
NHGRI. The ENCODE project was launched to reveal how
genetic instructions are read on a global, genome-wide scale
[46]. As a result of the ENCODE effort, a detailed picture of
human genome organization is emerging which includes the
mapping of transcribed regions [47], DNA binding of transcrip-
tion factors [48], and the structure and modifications of chroma-
tin states [49]. Collectively, the project surveys the landscape of
the Homo sapiens and Mus musculus genomes using over 20 high-
throughput genomic assays in >350 different cell and tissue
types, resulting in over 3000 data sets [50, 51]. This information
is informative to both basic and disease-related human biology
[52]. The ENCODE portal is the primary repository to access,
view and download all data generated by the ENCODE consor-
tium (http://www.encodeproject.org). Direct interaction with
the ENCODE Data Coordination Centre database can be per-
formed by the ENCODE REST API. Furthermore, a number of
software tools help users to use the ENCODE data in their own
analyses (https://www.encodeproject.org/software). Besides
providing users with an unprecedented amount of data from
state-of-the-art functional genome-wide assays, the ENCODE
project has set the stage for developing computational
approaches to correlate multiple data types and derive
quantitative models of gene expression regulation [49].
The ENCODE project has been used as a resource for
common diseases other than cancer, including insulin resist-
ance [53] and kidney disease [54]. GWAS profiling has been used
to identify dysregulated genes in autoimmune disease [55]. The
common theme of these studies has been to connect disease-
associated genes with their controlling regulatory elements.
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Functional Annotation of Mammalian Genomes 5
The Functional Annotation of Mammalian Genomes 5 (FANTOM5)
(http://fantom.gsc.riken.jp/5/) project aims at building transcrip-
tional regulatory models for every primary cell type that makes up
a human. The RIKEN-led FANTOM5 consortium systematically in-
vestigates the sets of genes used in virtually all cell types across
the human body, and the genomic regions which determine
where the genes are read from. What emerges from applying Cap
Analysis of Gene Expression to the majority of mammalian pri-
mary cell types and a selection of cancer cell lines and tissues is a
fined and context-specific map of sets of active transcripts, tran-
scription factors, promoters and enhancers [56, 57]. More recently,
a comprehensive analysis of RNA expression in 19 human time
courses showed that enhancer transcription is the earliest event
in successive waves of transcriptional changes when cells
undergo phenotype changes such as differentiation into special-
ized cell types [58]. To help wet-bench and computational users to
examine the diverse and large number of samples, the FANTOM5
consortium assembled the FANTOM Five Sample Ontology lever-
aging on the existing basic ontologies regarding cell types (CL),
anatomical systems (UBERON) and diseases (DOID). Primary data
visualization system for FANTOM5 is the ZENBU genome browser
and analysis system. All data generated by the FANTOM5 project
can also be accessed by using a semantic catalog of samples, tran-
scription initiation and regulators or by sub-setting data of interest
through the Table Extraction Tool [59].
Ensembl Regulatory Build
The Ensembl Regulatory Build aims at providing an up-to-date
and systematic overview of regulatory elements by integrating
the large amounts of valuable data released into the public
domain from the aforementioned projects as well as from
medium-scale studies [60].
Microarray repositories
Gene Expression Omnibus
Multi-assay genomic experiments are increasingly within reach
of individual laboratories, and GEO is the primary database where
data from these experiments are shared publicly. Data from GEO
can be challenging to use because (1) data sets are challenging to
find among the >57 000 data series and 14 000 technological plat-
forms provided at time of writing, and (2) important aspects of
data sets such as gene identifiers and clinical annotations are
not consistent between data sets. The first challenge can be ap-
proached using the ‘GEOmetadb’ Bioconductor package [61],
which provides a SQLite database of all GEO metadata that can be
accessed through SQL queries or simplified interfaces such as the
‘dplyr’ library [62]. We used ‘GEOmetadb’ to identify all 3910 GEO
series providing more than one genomic data type (Table 3), and
plotted the number of the six most common data types appearing
among these series each year since the first series with mul-
tiple data types appeared in 2003 (Figure 3). Code for these
analyses are provided at https://github.com/seandavi/
MultiplatformGEOSurvey. Data sets identified by this approach
can be downloaded in uncurated form to the Bioconductor envir-
onment [63] using ‘GEOquery’ [64].
ArrayExpress
ArrayExpress (https://www.ebi.ac.uk/arrayexpress/) [65] is the
European counterpart of GEO and also a major resource for
experimental data from individual laboratories. ArrayExpress
lacks an equivalent of ‘GEOmetadb’ but does have an interface
to Bioconductor [66].
Georgetown Database of Cancer Plus other diseases
The Georgetown Database of Cancer (G-DOC) Plus (https://gdoc.
georgetown.edu/gdoc/) provides ‘omics’ data from 59 clinical
studies covering 10 201 patients, including 10 cancer types and
other diseases such as dementia, muscular dystropy and wound
healing. The repository provides individual patient data includ-
ing demographics, clinical outcome, and tumor pathology. The
data in G-DOC Plus are uniformly processed in Bioconductor,
and then uploaded to the central database.
Expression Quantitative Trait Loci studies
Expression Quantitative Trait Loci (eQTL) studies are possibly the
most common existing examples of multi-assay genomic ana-
lysis. The aim of eQTL studies, where mRNA expression levels
are considered as quantitative traits, is the identification of gen-
etic variants affecting gene regulation [67]; to this end, eQTL stud-
ies integrate genotypic and expression data. In human studies,
the genotype portion of eQTL experiments is often not made pub-
licly available because of privacy concerns. The Genotype-Tissue
Expression project (http://www.gtexportal.org) [68, 69] is to our
knowledge the most comprehensive data resource for gene ex-
pression and genotype across multiple human tissues, and pro-
vides genotype data to verified researchers. GTEx and other
major gene regulation catalogs were recently summarized [70].
STATegra
STATegra (http://www.stategra.eu) profiles a well-established
model of cell-system B-cell progenitor differentiation including
Hardy fractions Fr.C’ to Fr.D (B3, [71]). Cells are assayed with
strand-specific RNA-seq, ChIP-seq, RRBS-seq, DNase-seq,
microRNA-seq, proteomics and metabolomics, to provide a con-
trolled system for investigating the different regulatory mech-
anisms of mRNA during a differentiation process. In contrast to
TCGA, where many data types are considered for different can-
cers, STATegra data provide a more detailed genomic profiling
over a limited number of biological replications. STATegra can
be considered as a snapshot of future projects where many
omics would be available for the same system. STATegra data
will become public by the second half of 2015, and will provide a
test case for data management and integrative analysis meth-
ods for extensive multi-assay profiling.
Genomic data sets for single-disease systems
Several highly curated ‘ExperimentData’ packages in
Bioconductor provide an easy and focused point of entry into
integrative genomic data analysis for single disease systems. The
Table 3. Multi-assay data sets in the GEO as of April, 2015. Data types
provided by every GEO series were queried using the ‘GEOmetadb’
Bioconductor package [61]
Number of data types Number of GEO series
1 53 066
2 3382
3 456
4 64
5 8
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curatedOvarianData package [72], for example, is a compendium
of 25 highly annotated gene expression data sets that encom-
passes over 3000 ovarian cancer clinically annotated gene and
microRNA expression profiles. These samples have been collated
across multiple studies from GEO, EBI Array Express, TCGA, as
well as individually archived datasets. Key clinical annotations
such as stage, grade, primary site, and outcome are present
across most data sets, but other variables such as patient
treatment information are mostly absent (Figure 4). The
curatedOvarianData package serves as a prime example of how
harmonization of public data sets can enable new hypothesis
testing and development of statistical methodology.
Tools for integrative genomic data analysis
Biological molecules are regulated at the transcriptional, trans-
lational, and post-translational level. Integrating different
molecular data may increase the power to more comprehen-
sively interrogate and understand the physiological system, but
novel methodologies are required to integrate these complex
data sets. We survey available tools in several categories before
concluding with the still-existing gaps in these tools.
Interactive visualization tools
We classify visualization tools by the usage of genomic coordin-
ates, heat maps, and networks. Extensive overviews of
visualization tools are available [73], and this section only
briefly surveys a few of the most popular alternatives.
Genome browsers such as the UCSC Cancer Genomics
Browser [74] and the Savant Genome Browser [75] allow data
visualization by genomic location, with addition of annotations
and data types as additional tracks. The Integrative Genomics
Viewer [76] additionally enables inspection of specific cancer
genomic loci or the general overview of genomic alterations, the
exploration of cause–effect relationships between various
alteration types. Most recently, the Epiviz genome browser [77]
provides both a web-based interface and full integration with
Bioconductor and its core data classes through the ‘Epivizr’
package. Visualization tools tied to genomic coordinates can be
troublesome in cancer genomes containing extensive
rearrangements, and when attempting to integrate data types
not associated with genomic coordinates. Alternate visualiza-
tion tools such as circle plots [78, 79] and canonical correlation
analysis methods are useful to circumvent the challenges posed
by rearrangements.
Several online resources preload data from TCGA, ICGC and
GEO, and generate heatmaps and other visualizations from
these data. cBioPortal (http://www.cbioportal.org) [11] is a popu-
lar Web interface, that presents results of integrative analyses,
visualizations, and selective downloads of TCGA and other can-
cer data sets. Direct programmatic queries to the cBioPortal can-
cer genomics data server (CGDS) is available using a REST API,
Matlab, and an R package (CGDS-R). IntOgen (http://www.
10
1000
2004 2006 2008 2010 2012 2014
Year
N
um
b
er
 o
f S
ub
m
is
si
on
s
type
Expression profiling by array
Expression profiling by high throughput sequencing
Genome binding/occupancy profiling by genome tiling array
Genome binding/occupancy profiling by high throughput sequencing
Non−coding RNA profiling by array
Non−coding RNA profiling by high throughput sequencing
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intogen.org) [80, 81] provides publicly available cancer genomic
data, as well as drug–protein interactions, to provide a point-
and-click interface to the integrative analysis of these data with
a focus on visualization of somatic mutations. Caleydo
StratomeX (http://caleydo.github.io/) [82] provides heatmaps,
stratification by clustering of multiple data types and by clinico-
pathological parameters, Kaplan-Meier plots, differential ex-
pression analysis, and gene set enrichment analysis for TCGA
data. Gitools [83] generates interactive heatmaps of TCGA as
well as IntOgen mutation data sets. GENE-E (unpublished,
http://www.broadinstitute.org/cancer/software/GENE-E) is yet
another tool focused on integrative genomic heatmaps, but
does not focus on preloaded data. The Regulome Explorer
(http://explorer.cancerregulome.org/all_pairs/) visualizes rela-
tionships between pairs of genomic measurements in an inter-
active circular link diagram.
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Figure 4. Overview of clinical annotation in the curatedOvarian data package. Clinicopathological characteristics of patients (columns) are represented across 25 gene
expression data sets (rows). For each data set, the percentage of patients in that data set that are annotated by a certain clinical characteristic is represented. Patient
treatment by platin, taxol or neoadjuvant therapy is presented as pltx, tax and neo, respectively.
Public data and open source tools for multi-assay genomic investigation of disease | 611
Data analysis and methodology development in
Bioconductor
The above tools provide predetermined analyses and visualiza-
tions, as opposed to software for open-ended exploratory data
analysis or development of integrative methodology. The
Bioconductor project [63] provides one of the most widely used,
most flexible and mature open source environments for such
purposes. Bioconductor provides statistical software for prepro-
cessing, normalization, analysis, integration, and visualization
of numerous molecular data types including exome, RNAseq,
methylation, microRNA, proteomics data. It is widely
considered the de facto statistical analysis suite for genomics
data. The major data classes are ‘GenomicRanges’ and
‘SummarizedExperiment’ for processed range-based data [84],
and ‘ExpressionSet’ for data represented by features such as
gene or microarray probeset identifiers [85]. These classes
greatly simplify record-keeping and integrative analysis of a
single data type with patient characteristics or other pheno-
types. ‘GenomicRanges’ and its associated ‘IRanges’ algebra
assist in the integration of multiple genome-anchored data
types through built-in operations to find intersections, unions,
flanking regions, etc of genomic ranges. However, base data
classes for multi-assay genomic experiments are still lacking.
Bioconductor enables integration with annotation resources
such as gene models, regulatory interactions, and maps between
alternative genomic feature identifiers. Organism-oriented, sys-
tems biology-oriented, and gene and transcript-oriented annota-
tion resources have been summarized (http://genomicsclass.
github.io/book/pages/annoCheat.html). Recently, major annota-
tion resources from ENCODE and the UCSC Genome Browser are
redistributed within Bioconductor via ‘AnnotationHub’.
We classify data integration methodologies under three
categories: exploratory data analysis, network analysis and
supervised meta-analysis. Exploratory data analysis enables
one to identify the major patterns in the data, including poten-
tial issues such as batch effects [86] and outliers. Multivariate
extensions of principal component analysis (PCA) and cluster-
ing analysis are useful tools to understand basic data structure,
inter-data set and intra-data set correlations. Some of the R
software available in this category are PMA [97], made4 [87],
MCIA [88], RGCCA [89]. Network analysis has been applied for
the integration of multiple data types. A common approach is to
combine an interaction network with molecular (e.g. genomic,
transcriptomic and proteomic) profiles reflecting condition-spe-
cific nodes activities or interaction strengths [91–92, 95]. In
supervised meta-analysis, the aim is to refine findings based on
one data type with additional analysis of further omics data
obtained from the same set of samples. Some of the available
software in this category are CNAmet [93], Rtopper [94],
iClusterPlus [95] and the STATegra Bioconductor package. We
note that these methods fall short of full systems biology data
integration, as they do not, for example, incorporate known
regulatory relationships between microRNA, RNA-binding pro-
tein or transcription factors, with gene expression. While a thor-
ough review of these resources is beyond the scope of this
review, we summarize some relevant R/Bioconductor packages
in Table 4, and refer readers to [96] for a comprehensive review
of genomic data analysis in Bioconductor.
Discussion
The data resources and toolsets outlined in this review are used
by disparate research communities, but integration across data
sets and data types remains limited. A significant barrier to
better utilization of these free resources is simply finding the
right data or tool among an overwhelming amount of loosely
organized information. The US NIH have recognized this barrier
and announced plans to develop a Data Commons (https://
pebourne.wordpress.com/2014/10/07/the-commons/) that will
serve as a metadata repository for data and software resources.
This review is written with a similar but more focused intent,
providing a much more focused snapshot of a resources for
multi-assay genomic data on human disease.
Sufficient computing infrastructure, and the cost of moving
large data sets to local infrastructure to compute on these data
sets can be an additional barrier. The Cancer Genomics Cloud
Pilots of the US NCI (https://cbiit.nci.nih.gov/ncip/nci-cancer-
genomics-cloud-pilots) is one experiment in addressing some
of these infrastructural limitations by co-location of computing
infrastructure, data and software, and commercial options are
also appearing. Flexible computing approaches, which maxi-
mize use of whatever resources are available, are needed. For
example, expression and phenotype data on samples may be
available as tables on local disk, while high-resolution genotype
data on the samples may be resident in cloud-based storage,
and a local cluster may have a large number of compute nodes
with modest memory volumes available to support machine
learning. Highly generic workflow specification is needed to
support derivation, from diverse sources and storage modal-
ities, of data subsets that are suitable inputs to statistical
algorithms. Distributed implementations of statistical algo-
rithms, with scalable memory footprints, must also be readily
usable by subject-matter specialists. The Bioconductor project
has experienced substantial recent advances in such scalable
Table 4. R packages for integrative data analysis
R/bioconductor package name Description Repository
PMA [97] Penalized multivariate analysis (sparse CCA, PCA) CRAN
mixOmics [98] rCCA, sPLS CRAN
sPLS-DA
rGCCA
made4 [87] Coinertia analysis Bioconductor
MCIA [88] Multi-CIA Bioconductor
RGCCA [89] rGCCA, sparse GCCA for multi-block data analysis CRAN
CNAmet [93] Signal-to-noise ratio statistic, permutation test csbi.ltdk.helsinki.fi/CNAmet/
Rtopper [94] Gene set enrichment Bioconductor
iClusterPlus [95] Joint latent variable regression model Bioconductor
STATegra (www.stategra.eu) PCA, clustering Bioconductor
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computing by streamlining programming idioms for embar-
rassingly parallel computation (BiocParallel package), creating
virtual machine images to simplify endowment of clusters with
strong numerical and inferential toolkits (Bioconductor AMI)
and emphasizing scalable data flow architecture both for assay
interrogation (record yield prescriptions for BAM archive
references in ‘Rsamtools’) and statistical computation (scatter-
gather accumulation of sufficient statistics in the ‘parglm’
package). There remain significant needs for input on strategy
selection for data storage, harvesting, and analysis processes.
Although abundant multi-assay genomic data resources
exist, software tools for their analysis are still severely lacking.
Available tools focus primarily on data acquisition and standard
visualization, and provide some common prespecified analyses.
True systems biology integration of different layers of genomic
data still requires custom coding and substantial bioinformatics
effort. The Bioconductor project comes closest to providing an
environment for systems biology integration with arbitrarily
flexible statistical analysis and visualization, but important de-
velopments are still needed. The creation of multi-assay con-
tainers will enable advanced quality control checks through the
assessment of known regulators effects on targets at multiple
levels such as DNA methylation versus mRNA transcription or
DNA copy number versus mRNA transcription. Fully integrative
analysis requires linking data types through annotation. A few
possible examples include linking microRNA and their targets,
associating exons with transcripts or transcripts with genomic
locations of respective genes or with other transcripts in known
pathways. All these annotations exist within the Bioconductor
environment, but facilities allowing straightforward integration
of them remains an area of active current development.
Key Points
• Although abundant multi-assay genomic data
resources exist, software tools for their analysis are
still in early stages.
• Available tools focus primarily on data acquisition and
visualization through genome browsers or heatmaps,
and providing some common prespecified analyses.
• Significant efforts are still needed to streamline
systems biology integration of different layers of gen-
omic data, and to integrate results from the major
data-generating projects.
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